GSK to acquire vaccine developer Affinivax in deal worth up to $3.3bn

GlaxoSmithKline (GSK) has agreed to acquire Affinivax, a Boston-based clinical-stage vaccine developer, in a deal worth up to $3.3 billion. The consideration includes an upfront ... Read More